spacer
home > ebr > Winter 2010
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2010

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

   
Text
PDF
bullet
Business Development and Financing

Using case studies from major players in the pharmaceutical industry, Peter Thornton at Business Insights reviews strategies to revitalise R&D and boost flagging pipelines.

 
view
download pdf

Implementing a ‘roadbook-controlled project’ that takes into account the development process and financial and risk parameters can limit the waste of invested money through strategically placed ‘go/no go’ decision points, explains Roel Bellens at Strategus.

 
view
download pdf

John Nash, Alan Beresford and Dawn Yates at BioFocus argue that outsourcing ADME to CROs can eliminate potential development liabilities, cut costs by reducing time spent on unsuitable candidates, and provide access to a wide range of testing resources.

 
view
download pdf

There is currently global political and economic pressure to reduce the costs of healthcare. Michael F Swanick at PricewaterhouseCoopers examines the impact that rising tax rates will have on the biopharmaceutical industry over the next year.

 
view
download pdf

The European Commission released its final report on the Pharmaceutical Sector Inquiry in July this year, and it clearly aims to promote practices that increase the level of generic entries. Michael McFalls and Frances Murphy at Jones Day compare the report to US legislation and fear that it may lead to limitations that are a step too far.

 
view
download pdf

As companies expand globally, it is crucial that they maintain their efficiency and reputation through effective communication structures. Simone Lamont and Alison Lamb of CLS Communication AG point out the benefits of using the services of life science language specialists that fully understanding your business, ensuring seamless integration.

 
view
download pdf
bullet
BioResearch and Innovation

Matthew Sleeman and Fabio Magrini at MedImmune review developments in using antibodies to treat autoimmune diseases and in other areas of unmet medical need, and hope that this will continue to stimulate research into the pathogenic mechanisms of autoimmunity.

 
view
download pdf

Cervical cancer is the second most common cancer in women, and around 80 per cent of deaths resulting from it occur in developing countries. Julie Zhu at QIAGEN discusses how tools and technologies can be adapted for low-resource settings to ensure that women at risk can be identified worldwide.

 
view
download pdf
bullet
Discovery Technology

Technological advances have led to quantitative polymerase chain reaction (qPCR) becoming a quality validation method for a range of scientific and medical approaches. Tobias Hampshire at Thermo Fisher Scientific provides an overview of recent developments in probe-based technology.

 
view
download pdf

miRNAs are ideally suited for use as biomarkers due to their role in controlling cellular activity. By indicating the biological state of cells and tissues, Peer Staehler at febit argues that they are important to diagnostics and may have the potential to become therapeutic targets and tools.

 
view
download pdf
bullet
BioDevelopment and Regulatory

Andy Bailey at ViruSure GmbH reviews the latest regulations leading towards a new approach to virus safety for investigational biotechnology products.

 
view
download pdf

Quality assurance should be integral to clinical development and trials to ensure the accuracy of test results. Martin Crockard at Randox describes different types of analyses and explains that the choice of scheme should be dependent on the size, duration and complexity of the trial.

 
view
download pdf
bullet
BioFormulation and Manufacturing

William Downey at HighTech Business Decisions provides an overview of the results of an investigation into the criteria that directors of biomanufacturing companies believed to be most important when choosing a contract manufacturing organisation.

 
view
download pdf

The move towards personalised medicine has meant that a great number of samples are collected during clinical trials. In order to manage this data, a flexible information system that works in real-time should be employed, explains Jennifer Benner at BioStorage Technologies.

 
view
download pdf
bullet
BioRegional

Bob Smailes at LeidenUniversity outlines the research taking place at LeidenBioSciencePark, the leading life science park in the Netherlands.

 
view
download pdf

A new cGMP production centre is being built in Wallonia, allowing three companies who work in the field of regenerative medicines to come together to create one platform, where each will have their own production space and the support they need.

 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

BioTrinity 2020

28-29 April 2020, Etc Venues, London

BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement